Neuralstem, Inc. (NASDAQ:CUR)’s share price traded down 35% during trading on Wednesday . The company traded as low as $2.01 and last traded at $2.01. 8,337,186 shares traded hands during mid-day trading, an increase of 1,258% from the average session volume of 613,819 shares. The stock had previously closed at $3.09.
A number of institutional investors have recently made changes to their positions in the business. National Asset Management Inc. increased its stake in Neuralstem by 9.2% in the 2nd quarter. National Asset Management Inc. now owns 22,985 shares of the company’s stock worth $134,000 after purchasing an additional 1,937 shares during the period. Vanguard Group Inc. increased its stake in Neuralstem by 1.1% in the 2nd quarter. Vanguard Group Inc. now owns 345,346 shares of the company’s stock worth $2,000,000 after purchasing an additional 3,853 shares during the period. Blair William & Co. IL increased its stake in Neuralstem by 171.0% in the 2nd quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock worth $506,000 after purchasing an additional 55,115 shares during the period. Finally, Alethea Capital Management LLC increased its stake in Neuralstem by 100.0% in the 2nd quarter. Alethea Capital Management LLC now owns 328,788 shares of the company’s stock worth $1,904,000 after purchasing an additional 164,394 shares during the period. 7.14% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Neuralstem (CUR) Trading Down 35%” was published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2017/12/06/neuralstem-cur-trading-down-35.html.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.